Clinical Trial

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Protocol Amendment History 36 amendments
This ClinicalTrials.gov record has been amended 36 times since 2024-10-11; most recent amendment 2026-07-07.
Status change: Not Yet Recruiting → Recruiting 2025-03-11
Trial Details
NCT Number NCT06641466
Lead Sponsor Pfizer
Conditions Menstrual Migraine
Enrollment 723 participants
Start Date 2025-03-11
Primary Completion 2026-11-29 (estimated)
Study Completion 2027-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-09